Dr. Andrew G. Hadd, Ph.D., Senior Scientist, Diagnostic Research & Technology Development, Asuragen, Inc.
Learn how Asuragen is applying the RainDance DeepSeq Solution to commercialize cancer prevention and research tools for their customers. Dr. Andrew Hadd, Ph.D. will discuss the design and implementation of the Asuragen SuraSeq™ 7500 panel. This panel targets 52 genes in which 21 genes are interrogated for the complete exons and 31 of the genes are targeted for known Cancer HotSpots. Dr. Hadd will present data demonstrating the sensitivity and specificity of the panel with clinical Colorectal Cancer (CCR) samples in addition to a set of control samples generated at Asuragen to test the sensitivity to detect rare mutations represented at 5%. Dr. Hadd will also show how they have reduced the starting amount of gDNA by 10-fold from 1,000 to 100 ng of input gDNA.